Induction Chemotherapy: To Use or Not to Use? That Is the Question

Seminars in Radiation Oncology

Volumn 19, Issue 1, 2009, Pages 11-16

  Brizel, David M ^a   Vokes, Everett E ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; PACLITAXEL;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DISEASE CONTROL; HEAD AND NECK CARCINOMA; HUMAN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OROPHARYNX CANCER; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; NEOADJUVANT THERAPY; REMISSION INDUCTION; TAXOIDS;

EID: 56349117582     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2008.09.003     Document Type: Review

References (35)

1. Bourhis J., Overgaard J., Audry H., et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet 368 (2006) 843-854
2. Pignon J.P., Bourhis J., Domenge C., et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355 (2000) 949-955
3. Monnerat C., Faivre S., Temam S., et al. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol 13 (2002) 995-1006
4. Forastiere A.A. Overview of platinum chemotherapy in head and neck cancer. Semin Oncol 21 (1994) 20-27
5. Kies M.S., Haraf D.J., Rosen F., et al. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol 19 (2001) 1961-1969
6. Adelstein D.J., Saxton J.P., Rybicki L.A., et al. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: Mature results from a single institution. J Clin Oncol 24 (2006) 1064-1071
7. Horiot J.C., Le Fur R., N′Guyen T., et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25 (1992) 231-241
8. Fu K.K., Pajak T.F., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48 (2000) 7-16
9. Overgaard J., Hansen H.S., Specht L., et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362 (2003) 933-940
10. Kasibhatla M., Kirkpatrick J.P., and Brizel D.M. How much radiation is the chemotherapy worth in advanced head and neck cancer?. Int J Radiat Oncol Biol Phys 68 (2007) 1491-1495
11. Seiwert T.Y., Cohen E.E., Haraf D.J., et al. A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer. Cancer Invest 25 (2007) 435-444
12. Haddad R., Tishler R.B., Norris C.M., et al. Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. Oncologist 8 (2003) 35-44
13. Janinis J., Papadakou M., Panagos G., et al. Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol 24 (2001) 227-231
14. Schrijvers D., Van Herpen C., Kerger J., et al. Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: A phase I-II feasibility study. Ann Oncol 15 (2004) 638-645
15. Vermorken J.B., Remenar E., van Herpen C., et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357 (2007) 1695-1704
16. Posner M.R., Hershock D.M., Blajman C.R., et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357 (2007) 1705-1715
17. Fountzilas G., Ciuleanu E., Dafni U., et al. Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: A Hellenic Cooperative Oncology Group Phase III Study. Med Oncol 21 (2004) 95-107
18. Vokes E.E., Herndon II J.E., Kelley M.J., et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25 (2007) 1698-1704
19. Hitt R., Lopez-Pousa A., Martinez-Trufero J., et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23 (2005) 8636-8645
20. Bensadoun R.J., Benezery K., Dassonville O., et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 64 (2006) 983-994
21. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338 (1998) 1798-1804
22. Denis F., Garaud P., Bardet E., et al. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: Comparison of LENT/SOMA. RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 55 (2003) 93-98
23. Jeremic B., Shibamoto Y., Milicic B., et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol 18 (2000) 1458-1464
24. Feng F.Y., Kim H.M., Lyden T.H., et al. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: Early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 68 (2007) 1289-1298
25. Lee W.T., Akst L.M., Adelstein D.J., et al. Risk factors for hypopharyngeal/upper esophageal stricture formation after concurrent chemoradiation. Head Neck 28 (2006) 808-812
26. Gwede C.K., Johnson D.J., Daniels S.S., et al. Assessment of toxicity in cooperative oncology clinical trials: The long and short of it. J Oncol Manag 11 (2002) 15-21
27. Trotti A., Bellm L.A., Epstein J.B., et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: A systematic literature review. Radiother Oncol 66 (2003) 253-262
28. Trotti A., and Bentzen S.M. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol 22 (2004) 19-22
29. Trotti A., Pajak T.F., Gwede C.K., et al. TAME: Development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol 8 (2007) 613-624
30. Brizel D.M., Murphy B.A., Rosenthal D.I., et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol 26 (2008) 2489-2496
31. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
32. Huguenin P., Beer K.T., Allal A., et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 22 (2004) 4665-4673
33. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 (2004) 1945-1952
34. Adelstein D.J., Lavertu P., Saxton J.P., et al. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 88 (2000) 876-883
35. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349 (2003) 2091-2098